Aquestive Therapeutics, Inc. Common Stock
Here’s whether Aquestive Therapeutics, Inc. Common Stock (AQST) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.87% over 10 days); strong 1-year return of +19.2%; 3-month momentum positive (+13.1%); rising volume confirms the move (1.73x 30d avg). Concerns: RSI 79 — overbought, elevated pullback risk. Currently 38.3% off its 52-week high. Score: +6/7.
AQST is in a confirmed uptrend, trading above both its 50-day ($4.17) and 200-day ($4.49) moving averages. With an RSI of 78.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +19.2% compares to +20.5% for SPY (trailed the market by 1.3%). The current 38.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.